Romiplostim
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Romiplostim: From Immune Thrombocytopenia to Platelet-Type Bleeding Disorder
One-Sentence Summary
Romiplostim is a thrombopoietin receptor (MPL) agonist originally used to raise platelet counts in chronic immune thrombocytopenia (ITP). The TxGNN model predicts it may also be effective for platelet-type bleeding disorder — a broader category covering chemotherapy-induced, transplant-related, and MDS-associated thrombocytopenia — with 8 clinical trials, including a completed Phase 3 randomized controlled trial, currently supporting this direction.
Note: Among the 10 TxGNN candidates in this evidence pack, “primary release disorder of platelets” received the highest raw model score, but its own mechanistic rationale flags a mismatch (it is a platelet-release defect, not a production deficit) and it is backed by only one low-relevance trial. “Platelet-type bleeding disorder” is presented here as the lead candidate because it has by far the strongest and most mechanistically consistent evidence base.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic immune thrombocytopenia (ITP) (from pharmacology clinical-use data; no local label on file) |
| Predicted New Indication | Platelet-type bleeding disorder |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L1 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action documentation from an official label is not available (data gap). Based on the pharmacology data on file, romiplostim is a peptide agonist of the thrombopoietin receptor (MPL, target gene MPL), and its efficacy in raising platelet counts in ITP is well established. Mechanistically, this receptor-agonist action stimulates megakaryocyte proliferation and maturation, which is not specific to autoimmune platelet destruction — it should, in principle, also compensate for insufficient platelet production from other causes.
“Platelet-type bleeding disorder,” as captured in the supporting trials, spans exactly this broader production-deficit population: chemotherapy-induced thrombocytopenia (RECITE trial), post-transplant delayed platelet engraftment, and MDS-associated thrombocytopenia. In each case the underlying problem — inadequate megakaryocyte-driven platelet output — is the same one romiplostim already treats in ITP, which is why the mechanistic extension is plausible and, unlike several other TxGNN candidates in this pack (e.g., pseudo-von Willebrand disease, Glanzmann thrombasthenia, Scott syndrome), does not conflict with the underlying disease pathology.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03362177 | Phase 3 | Completed | 165 | RECITE: randomized, placebo-controlled, double-blind trial of romiplostim for chemotherapy-induced thrombocytopenia in oxaliplatin-treated GI/pancreatic/colorectal cancer patients — highest-quality direct evidence |
| NCT05492409 | Phase 3 | Completed | 160 | Extension study of long-term safety/immunogenicity of a romiplostim-class agent (GNR-069) in ITP patients |
| NCT02335268 | Phase 2 | Completed | 77 | EUROPE trial: prospective validation of a response-prediction model for romiplostim in low/int-1 risk MDS with thrombocytopenia |
| NCT04638829 | Phase 4 | Completed | 60 | Real-world safety/treatment-satisfaction study in chronic ITP patients switching off romiplostim/eltrombopag |
| NCT02046291 | Phase 1 | Completed | 21 | Dose-escalation safety study of romiplostim for failed platelet engraftment after umbilical cord blood transplant |
| NCT02298075 | N/A | Completed | 148 | Retrospective study of sustained response after discontinuing TPO-receptor agonists (romiplostim/eltrombopag) in primary ITP |
| NCT02227576 | Phase 2 | Terminated | 20 | Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in glioblastoma (terminated — reason not detailed in this record) |
| NCT07321626 | Phase 1 | Recruiting | 130 | Ongoing randomized study of romiplostim for platelet reconstruction after haploidentical allogeneic stem cell transplant |
Literature Evidence
Currently no related literature available for this specific indication cluster.
India Market Information
Romiplostim currently has 0 registered authorizations and is not marketed in this jurisdiction (taiwan_regulatory dataset). No license records are available to summarize.
Safety Considerations
- Drug Interactions: Major-level interaction reported with Carfilzomib (source: DDInter) — combined use warrants close monitoring given the overlapping thrombocytopenia/thrombosis risk profile of both agents.
Detailed label-based warnings and contraindications are not yet available for this drug (data gap, TFDA label pending retrieval); please refer to the official package insert once obtained.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 3 placebo-controlled RCT (RECITE) plus a second completed Phase 3 study directly support romiplostim’s efficacy across production-deficit thrombocytopenias, and the underlying MPL-agonist mechanism is already clinically validated in ITP — but the drug is currently unregistered locally and key safety documentation is missing.
To proceed, the following is needed:
- TFDA/local label warnings and contraindications (DG001, blocking)
- Verified mechanism-of-action documentation from DrugBank (DG002)
- Local regulatory filing/registration pathway, given current “not marketed” status
- A defined monitoring and management protocol for the Major Carfilzomib interaction
- Clarification of the termination reason for NCT02227576 before relying on that data point
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.